Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT07749287

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07749287
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07749287. Randomized; double masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2023-01-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke
Acronym
NAC - H2S
Condition
Ischemic Cerebral Infarction
Intervention (Drug)
N Acetyl cysteine 600mg
Intervention (Drug)
Normal (0.9%) saline
Lead sponsor
Helwan University (class: other)

Record details

Record id
cardio:ct-nct07749287
Content hash
5e77fb337204b265bafb4e21b3bc56a1ed9d9a0c6ae14bb4d5db9d79092a0911